Drug Profile
H 39484
Alternative Names: H 394/84Latest Information Update: 07 Jan 2004
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Phenylurea compounds
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 07 Jan 2004 No development reported - Preclinical for Vascular disorders in Sweden (unspecified route)
- 11 Sep 2001 Preclinical development for Vascular disorders in Sweden (Unknown route)